Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; Modulating influence of TNF-α cytokine genetic polymorphism

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Mandegary, Ali ^a   Saeedi, Arastoo ^b   Eftekhari, Aziz ^a   Montazeri, Vahideh ^a   Sharif, Elham ^c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatoprotective; Hydrogen sulfide; Occupational toxicology; Polymorphism; Silymarin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HYDROGEN SULFIDE; NATURAL GAS; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SILYMARIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER FUNCTION TEST; LIVER PROTECTION; OXIDATIVE STRESS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 84876231225     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-28     Document Type: Article

References (29)

1. Oxidative stress induced in the workers of natural gas refineries, no role for GSTM1 and GSTT1 polymorphisms. Mandegary A, Sezavar M, Saeedi A, Amirheidari B, Naghibi B, Hum Exp Toxicol 2012 31 1271 1279 10.1177/ 0960327112450898 22736250
2. H2S cytotoxicity mechanism involves reactive oxygen species formation and mitochondrial depolarisation. Eghbal MA, Pennefather PS, O'Brien PJ, Toxicology 2004 203 69 76 10.1016/j.tox.2004.05.020 15363583
3. Hydrogen sulfide induces direct radical-associated DNA damage. Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ, Mol Cancer Res 2007 5 455 459 10.1158/1541-7786.MCR-06-0439 17475672
4. Oxidative stress and antioxidants in hepatic pathogenesis. Ha HL, Shin HJ, Feitelson MA, Yu DY, World J Gastroenterol 2010 16 6035 6043 10.3748/wjg.v16.i48.6035 21182217
5. Reactive oxygen and mechanisms of inflammatory liver injury: Present concepts. Jaeschke H, J Gastroenterol Hepatol 2011 26 Suppl 1 173 179 21199529
6. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Pradhan SC, Girish C, Indian J Med Res 2006 124 491 504 17213517
7. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Saller R, Brignoli R, Melzer J, Meier R, Forsch Komplementmed 2008 15 9 20 10.1159/000113648 18334810
8. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. Tsai JH, Liu JY, Wu TT, Ho PC, Huang CY, Shyu JC, Hsieh YS, Tsai CC, Liu YC, J Viral Hepat 2008 15 508 514 10.1111/j.1365-2893. 2008.00971.x 18397225
9. Effect of silymarin on different acute inflammation models and on leukocyte migration. De La Puerta R, Martinez E, Bravo L, Ahumada MC, J Pharm Pharmacol 1996 48 968 970 10.1111/j.2042-7158.1996.tb06014.x 8910865
10. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Katiyar SK, Int J Oncol 2005 26 169 176 15586237
11. Role of inflammation in chemical-induced hepatotoxicity. Luster MI, Simeonova PP, Gallucci RM, Bruccoleri A, Blazka ME, Yucesoy B, Toxicol Lett 2001 120 317 321 10.1016/S0378-4274(01)00284-3 11323190
12. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Shaker E, Mahmoud H, Mnaa S, Food Chem Toxicol 2010 48 803 806 10.1016/j.fct.2009.12.011 20034535
13. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. Fabris C, Soardo G, Falleti E, Toniutto P, Vitulli D, Federico E, Del Forno M, Mattiuzzo M, Gonano F, Pirisi M, J Interferon Cytokine Res 1998 18 705 709 10.1089/jir.1998.18.705 9781809
14. Cytokine gene polymorphism in human disease: on-line databases. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S, Genes Immun 1999 1 3 19 10.1038/sj.gene.6363645 11197303
15. Cell signaling in oxidative stress-induced liver injury. Czaja MJ, Semin Liver Dis 2007 27 378 389 10.1055/s-2007-991514 17979074
16. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. Abbas Z, Moatter T, Hussainy A, Jafri W, World J Gastroenterol 2005 11 6656 6661 16425360
17. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A, Arthritis Res Ther 2006 8 42 10.1186/ar1897 16507146
18. A simple salting out procedure for extracting DNA from human nucleated cells. Miller SA, Dykes DD, Polesky HF, Nucleic Acids Res 1988 16 1215 10.1093/nar/16.3.1215 3344216
19. Gluthatione-s-transferase T1-null Genotype predisposes adults to acute promyelocytic leukemia; a case-control study. Mandegary A, Rostami S, Alimoghaddam K, Ghavamzadeh A, Ghahremani MH, Asian Pacific J Cancer Prev 2011 12 1279 1282
20. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV, Transpl Immunol 1999 7 127 128 10.1016/S0966-3274(99)80030-6 10544444
21. Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD. Cheng SL, Yu CJ, Chen CJ, Yang PC, Eur Respir J 2004 23 818 824 10.1183/09031936.04.00104904 15218992
22. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N, Ino T, Utsunomiya A, Maruta A, Jin-nai I, Kamada N, Kubota Y, Nakamura H, Shimazaki C, Horiike S, Kodera Y, Saito H, Ueda R, Wiemels J, Ohno R, Clin Cancer Res 2000 6 4091 4095 11051261
23. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW, Proc Natl Acad Sci USA 1997 94 3195 3199 10.1073/pnas.94.7.3195 9096369
24. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. Videla LA, World J Hepatol 2009 1 72 78 10.4254/wjh.v1.i1.72 21160968
25. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Schwabe RF, Brenner DA, Am J Physiol Gastrointest Liver Physiol 2006 290 583 589 10.1152/ajpgi.00422.2005 16537970
26. Tumor necrosis factor polymorphisms and alcoholic liver disease: a HuGE review and meta-analysis. Marcos M, Gomez-Munuera M, Pastor I, Gonzalez-Sarmiento R, Laso FJ, Am J Epidemiol 2009 170 948 956 10.1093/aje/kwp236 19755636
27. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Wilson AG, di Giovine FS, Blakemore AI, Duff GW, Hum Mol Genet 1992 1 353 1363876
28. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Kroeger KM, Carville KS, Abraham LJ, Mol Immunol 1997 34 391 399 10.1016/S0161-5890(97)00052-7 9293772
29. Association between elevated serum hepatic enzyme activity and total body fat in obese humans. Choi JW, Ann Clin Lab Sci 2003 33 257 264 12956439